Get to know our clinical trials
Clinical trial for the long-term treatment of patients with cancer who have participated in BMS parent studies investigating adagrasib (BMS-986503).
THIS STUDY IS DESIGNED TO COLLECT LONG-TERM SAFETY DATA AND PROVIDE UNINTERRUPTED STUDY TREATMENT TO PARTICIPANTS WITH SOLID TUMORS WHO CONTINUE TO BENEFIT FROM ADAGRASIB IN AN ELIGIBLE CLINICAL TRIAL (PARENT STUDY).
Technical Summary
- SOLID TUMOR STUDY FOR THE LONG-TERM TREATMENT OF PATIENTS WITH CANCER WHO HAVE PARTICIPATED IN BMS PARENT STUDIES INVESTIGATING ADAGRASIB (BMS-986503).
- Code EudraCT: 2025-524905-34
- Protocol number: CA239-0071
- Promoter: BMS
- Molecule/Drug: Adagrasib
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.